REG - Life Science REIT - Result of AGM

Life Science ReitAnnouncement

Tue 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250603:nRSC2750La&default-theme=true

RNS Number : 2750L  Life Science REIT PLC  03 June 2025

Life Science REIT plc

(the "Company")

 

LEI: 213800RG7JNX7K8F7525

 

3 June 2025

 

Annual General Meeting ("AGM") Results

The Company announces that at its Annual General Meeting held earlier today
all the resolutions set out in the Notice of Annual General Meeting were
passed. All resolutions were voted on by way of a poll.  The results of the
poll for each resolution were as follows:

 

                                                                                 For                     Against

 Resolution                                                                                                                       Votes Withheld

                                                                                                                                  (No. of shares)

                                                                                 No. of shares           No. of shares  %

                                                                                                %

                                                                                 170,107,273    99.00%   1,725,065      1.00%     73,670

 1.   To receive and approve the annual report and financial statements

 2.   To receive and approve the Directors' remuneration report                  170,955,999    99.53%   803,872        0.47%     146,137

 3.   To approve the Directors' remuneration policy                              170,735,896    99.40%   1,025,053      0.60%     145,059

 4.   To approve the Company's dividend payment policy                                          99.70%   509,154        0.30%     108,336

                                                                                 171,288,518

 5.   To re-elect Claire Boyle as a Director of the Company                                     94.32%   9,756,368      5.68%     80,341

                                                                                 162,069,299

 6.   To re-elect Mike Taylor as a Director of the Company                                      98.04%   3,367,646      1.96%     80,341

                                                                                 168,458,021

 7.   To re-elect Richard Howell as a Director of the Company                                   98.04%   3,367,646      1.96%     80,341

                                                                                 168,458,021

 8.   To re-elect Sally Ann Forsyth as a Director of the Company                                93.35%   11,424,491     6.65%     80,341

                                                                                 160,401,176

                                                                                 171,653,308    99.90%   179,030        0.10%     73,670

 9.   To re-appoint Deloitte LLP as Auditor to the Company

 10.  To authorise the Audit and Risk Committee to determine the remuneration    171,676,363    99.92%   132,968        0.08%     96,677
 of the Auditor to the Company

 11.  To authorise the Directors to allot equity securities                                     93.03%   11,569,169     6.97%      5,829,866

                                                                                 154,506,973

                                                                                 144,015,864    86.72%   22,060,278     13.28%    5,829,866

 12.  To authorise the Directors to disapply pre-emption rights*

                                                                                 143,882,140    86.70%   22,067,565     13.30%    5,956,303

 13.  To authorise the Directors to disapply pre-emption rights for the
 purposes of financing an acquisition or other capital investment*

                                                                                  167,087,012            4,745,326      2.76%     73,670

 14.  To approve the purchase of the Company's own shares*                                      97.24%

 15.  That a general meeting, other than an AGM, may be called on not less       168,132,129    97.85%   3,700,209      2.15%     73,670
 than 14 clear days' notice*

 

*special resolution

 

 NOTES:

 1.      All resolutions were passed.

 2.      Percentages have been rounded to two decimal places.

 3.      Proxy appointments which gave discretion to the Chair of the AGM have been
         included in the "For" total for the appropriate resolution.

 4.      Votes "For" and "Against" any resolution are expressed as a percentage of
         votes validly cast for that resolution.

 5.      A "Vote withheld" is not a vote in law and is not counted in the calculation
         of the percentage of shares voted "For" or "Against" any resolution.

 6.      The number of shares in issue at 10:00 am. on 30 May 2025 was 350,000,000
         ordinary shares, carrying one vote each, and at that time, the Company did not
         hold any shares in treasury.

 7.      The full text of the resolutions passed at the AGM can be found in the Notice
         of Annual General Meeting which is available on the Company's website at
         https://lifesciencereit.co.uk/investors/shareholder-information/
         (https://lifesciencereit.co.uk/investors/shareholder-information/)

 

Enquiries:

 MUFG Corporate Governance Limited - Company Secretary
 labs_cosec@cm.mpms.mufg.com

 Ironstone Asset Management - Investment Adviser
 Simon Farnsworth/ Joanna Waddingham                                  via FTI Consulting below

 Panmure Liberum - Financial Adviser & Corporate Broker               +44 20 7886 2500
 Alex Collins / Tom Scrivens
 G10 Capital Limited - AIFM                                           +44 20 7397 5450
 Verity Morgan-Jones / Maria Baldwin

 FTI Consulting - PR Adviser                                          +44 20 3727 1000
 Dido Laurimore / Richard Gotla / Oliver Parsons
 LifeScienceReit@fticonsulting.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFJMITMTAMBPA